Cargando…

Role of combining neutrophil-to-lymphocyte ratio and pretreatment body mass index in predicting progression-free survival in patients with non-small cell lung cancer treated with nivolumab

Identifying markers capable of predicting outcomes in lung cancer patients treated with nivolumab represents a growing research interest. The combination of neutrophil-to-lymphocyte ratio (NLR) and body mass index (BMI) may help predict treatment efficacy. Thus, the present study aimed to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dragomir, Radu, Dragomir, Adelina Silvana, Negru, Alina, Săftescu, Sorin, Popovici, Dorel, Schenker, Michael, Lupușoru, Raluca, Negru, Șerban
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014982/ https://www.ncbi.nlm.nih.gov/pubmed/33815599 http://dx.doi.org/10.3892/etm.2021.9958

Ejemplares similares

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Anthropometry in the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Exploring the Influence of Age, Gender and Body Mass Index on Colorectal Cancer Location
por: Popovici, Dorel, et al.
Publicado: (2023)

Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study
por: Dragomir, Radu, et al.
Publicado: (2021)

Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
por: Săftescu, Sorin, et al.
Publicado: (2021)

Endurance of erythrocyte series in chemotherapy
por: Săftescu, Sorin, et al.
Publicado: (2020)

Comparative hematological profiles for dose-dense vs. regular anthracycline-based neoadjuvant chemotherapy in non-metastatic breast cancer
por: Popovici, Dorel, et al.
Publicado: (2021)

Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years. Follow-Up Data
por: Oprean, Cristina Marinela, et al.
Publicado: (2020)

Determining factors of renal dysfunction during cisplatin chemotherapy
por: Săftescu, Sorin, et al.
Publicado: (2021)

Associations between Body Mass Index and Prostate Cancer: The Impact on Progression-Free Survival
por: Popovici, Dorel, et al.
Publicado: (2023)

Neoplasia-Associated Pericarditis—Predictor of Cancer Progression?
por: Boldan, Anca, et al.
Publicado: (2021)

Nutritional Interventions to Improve Cachexia Outcomes in Cancer—A Systematic Review
por: Braha, Adina, et al.
Publicado: (2022)

Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study
por: Roman, Deiana, et al.
Publicado: (2022)

The Role of Nut and Seed Consumption in Colorectal Cancer: A Narrative Review
por: Roman, Deiana, et al.
Publicado: (2022)

The evaluation of pretreatment neutrophil–lymphocyte ratio and derived neutrophil–lymphocyte ratio in patients with laryngeal neoplasms()
por: Eskiizmir, Gorkem, et al.
Publicado: (2018)

The Association of Nonalcoholic Fatty Liver Disease With Neutrophil-to-Lymphocyte Ratio and Neutrophil-Percentage-to-Albumin Ratio
por: Cucoranu, Dragoș Constantin, et al.
Publicado: (2023)

Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
por: Gannichida, Ako, et al.
Publicado: (2022)

Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer
por: Takeda, Takayuki, et al.
Publicado: (2018)

Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma
por: Najjar, Marc, et al.
Publicado: (2018)

Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Pediatric Parotid Cancer
por: Seng, Dongjie, et al.
Publicado: (2019)

Prognostic Utility of Pretreatment Neutrophil-Lymphocyte Ratio in Advanced Larynx Cancer
por: Kotha, Nikhil V, et al.
Publicado: (2021)

Prognostic Relevance of Pretreatment Peripheral Neutrophil Count and Neutrophil-to-lymphocyte Ratio in Primary Cutaneous Angiosarcoma
por: AWAJI, Kentaro, et al.
Publicado: (2021)

Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients
por: Jonska-Gmyrek, Joanna, et al.
Publicado: (2018)

Pretreatment neutrophil-to-lymphocyte ratio predicts the prognosis in patients with metastatic prostate cancer
por: Kawahara, Takashi, et al.
Publicado: (2016)

Pretreatment Neutrophil–Lymphocyte Ratio: An Independent Predictor of Survival in Patients With Hepatocellular Carcinoma
por: Gao, Fangyuan, et al.
Publicado: (2015)

Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients
por: Cheng, Guangyan, et al.
Publicado: (2019)

Pretreatment neutrophil-to-lymphocyte ratio in peripheral blood was associated with pulmonary tuberculosis retreatment
por: Yin, Yongmei, et al.
Publicado: (2016)

The Role of Pretreatment Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in the Diagnosis of Breast Cancer: Predicting Lymph Node Metastasis
por: Eroglu, Aydan, et al.
Publicado: (2013)

Prognostic Significance of Pretreatment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma
por: Wang, Siqian, et al.
Publicado: (2018)

Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
por: Deng, Min, et al.
Publicado: (2017)

Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma
por: Lee, Su-Min, et al.
Publicado: (2015)

Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet−to−Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta−analysis
por: Leng, Jiali, et al.
Publicado: (2022)

Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer
por: Prabawa, I Putu Yuda, et al.
Publicado: (2019)

Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer
por: Wang, Xin, et al.
Publicado: (2016)

Predictive Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma
por: Chen, Miao-Fen, et al.
Publicado: (2018)

Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio in Mucoepidermoid Carcinoma of Pediatrics: A Multicenter Study
por: Gao, Hua, et al.
Publicado: (2020)

Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy
por: Du, Songtao, et al.
Publicado: (2021)

Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
por: Iinuma, Koji, et al.
Publicado: (2021)

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab
por: Liu, Jingjing, et al.
Publicado: (2019)

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab
por: Suzuki, Shinsuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3s78o4djhb963kk479qksjujd7